MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need.

$6.27  +0.12 (1.87%)
As of 09/26/2022 14:25:08 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/28/2017
Outstanding shares:  97,169,348
Average volume:  1,245,983
Market cap:   $597,591,490
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BF3NP05
Valuation   (See tab for details)
PE ratio:   -3.53
PB ratio:   4.11
PS ratio:   288.83
Return on equity:   -129.96%
Net income %:   -8,826.73%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy